2-(4-butoxy-3-methoxyphenyl)ethan-1-amine | 86457-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-butoxy-3-methoxyphenyl)ethan-1-amine
• 英文别名: 4-butoxy-3-methoxy-phenethylamine；4-Butoxy-3-methoxy-phenaethylamin；2-(4-Butoxy-3-methoxyphenyl)ethanamine
• CAS: 86457-00-3
• 化学式: C₁₃H₂₁NO₂
• 分子量: 223.315
• InChiKey: KTAZFRWTCOUPJW-UHFFFAOYSA-N

物化性质

• 沸点：
  145 °C(Press: 10 Torr)
• 密度：
  0.999±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-butoxy-3-methoxyphenyl)ethan-1-amine 在 PPA 、 Polyphosphoric acid (PPA) 作用下， 反应 9.0h， 生成 7-Butoxy-6-methoxy-3,4-dihydroisoquinoline
  参考文献：
  名称：

  Synthesis and antihypertensive activity of a series of spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one]s

  摘要：

  The 2R*,11bS* and 2S*,11bS* diastereoisomers of the spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2, 5'-oxazolidin-2'-one] system were prepared by stereoselective methods. Evaluation of these compounds for antihypertensive activity by oral administration to the spontaneously hypertensive rat showed the 2S*,11bS* series was the more potent. Within that series it was found that small alkyl substituents at positions 3 and 4' enhanced antihypertensive activity and that methoxyl substitution at positions 9 and 10 was optimal. (2S,3S,11bS)-Spiro-[2-ethyl-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one] [(-)-9e] was one of the most efficacious compounds of this series, while its antipode, (+)-9e, was inactive. Selected compounds in this series were shown to be alpha-adrenoceptor antagonists.

  DOI：

  10.1021/jm00364a013
• 作为产物：
  描述：

  3-(4-butoxy-3-methoxy-phenyl)-propionic acid 在 次溴酸钾 、 五氯化磷 作用下， 生成 2-(4-butoxy-3-methoxyphenyl)ethan-1-amine
  参考文献：
  名称：

  Sen; Arora, Journal of the Indian Chemical Society, 1959, vol. 36, p. 349,352

  摘要：

  DOI：

文献信息

• [EN] ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS
  申请人：UNIV RUTGERS

  公开号：WO2011156626A1

  公开（公告）日：2011-12-15

  The invention provides a compound of formula (I), or a salt or prodrug thereof, wherein R1, R4-R8, R10, R2'-R6', W, and A have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibacterial agents.

  该发明提供了一种化合物，其化学式为(I)，或其盐或前药，其中R1、R4-R8、R10、R2'-R6'、W和A具有规范中描述的任何值，以及包含化合物(I)的组合物。这些化合物可用作抗菌剂。
• Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α_1A-Adrenoceptor Antagonists
  作者：Diliang Guo、Jing Li、Henry Lin、Yu Zhou、Ying Chen、Fei Zhao、Haifeng Sun、Dan Zhang、Honglin Li、Brian K. Shoichet、Lei Shan、Weidong Zhang、Xin Xie、Hualiang Jiang、Hong Liu

  DOI：10.1021/acs.jmedchem.6b01217

  日期：2016.10.27

  A novel series of tetrahydroprotoberberine derivatives (THPBs) were designed, synthesized, and evaluated as selective α1A-adrenergic receptors (AR) antagonists for the treatment of benign prostatic hyperplasia. On the basis of the pharmacophore model of the marketed drug silodosin, THPBs were modified by introducing an indole segment into their core scaffolds. In calcium assays, 7 out of 32 compounds

  一种新型系列tetrahydroprotoberberine衍生物（THPBs）的设计，合成和评价为选择性α 1A肾上腺素能受体（AR）拮抗剂用于良性前列腺增生的治疗。根据市售的药物西洛多辛的药效团模型，通过将吲哚片段引入其核心支架来修饰THPB。在钙化验中，32种化合物中有7种对α1A -ARs表现出优异的拮抗活性，IC 50小于250 nM。其中，化合物（S）-27具有最强的生物活性。其对α1A -AR的IC 50为12.8±2.2 nM，是对α1A -AR的781和20倍。1B -和α 1D -AR，分别。在使用离体大鼠组织的功能测定中，化合物（S）-27有效抑制去甲肾上腺素引起的尿道平滑肌收缩（IC 50 = 0.5±0.3 nM），而没有抑制主动脉收缩（IC 50 > 1000 nM），表现出更好的效果。组织选择性优于市售药物西洛多辛。初步安全性研究（急性毒性和hERG抑制作用）
• [EN] TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS TÉTRAHYDROPROTOBERBINES ET LEURS UTILISATIONS DANS LE TRAITEMENT DE MALADIES NEUROLOGIQUES, PSYCHIATRIQUES ET NEURODÉGÉNÉRATIVES
  申请人：MILLER JAMES JACKSON

  公开号：WO2013020229A1

  公开（公告）日：2013-02-14

  Tetrahydroprotoberbine (THPB) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-THPBs of general formula (I). Enantioselective processes for preparing compounds of formula (I), and d- and l-govadine are also provided.(I)

  提供了Tetrahydroprotoberbine (THPB)化合物及其在治疗神经系统、精神疾病和神经退行性疾病中的用途。这些化合物包括d-govadine、l-govadine和racemic govadine，以及通式(I)的d-THPBs。还提供了制备通式(I)化合物和d-、l-govadine的对映选择性过程。(I)
• 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：Hwang On-You

  公开号：US20100217003A1

  公开（公告）日：2010-08-26

  Provided are 7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline derivatives and synthesis methods thereof. The compounds significantly inhibit the production of nitrogen monoxide (NO) and superoxide in an activated microglial cell and expressions of TNF-α, IL-1β inducive NO synthase and cyclooxygenase-2 genes. They also prevent NF-kB shift to a nucleus, decrease reactive oxygen species (ROS), inhibit expression of GTP cyclohydrolase I gene and over-production of tetrahydrobiopterin (BH 4 ), and protect dopaminergic neurons from injury due to activated microglial cells. Consequently, the compounds are effective in treating inflammatory and neurodegenerative diseases.

  提供了7-羟基-6-甲氧基-1,2,3,4-四氢异喹啉衍生物及其合成方法。这些化合物显著抑制活化小胶质细胞中一氧化氮（NO）和超氧化物的产生，以及TNF-α、IL-1β诱导NO合成酶和环氧合酶-2基因的表达。它们还可以防止NF-kB转移到细胞核，降低活性氧自由基（ROS）的水平，抑制GTP环水合酶I基因的表达和四氢生物蝶呤（BH4）的过度产生，并保护多巴胺能神经元免受活化小胶质细胞引起的损伤。因此，这些化合物对于治疗炎症和神经退行性疾病具有有效性。
• ANTIMICROBIAL AGENTS
  申请人：Lavoie Edmond J.

  公开号：US20130116278A1

  公开（公告）日：2013-05-09

  The invention provides a compound of formula (I): or a salt or prodrug thereof, wherein R 1 , R 4 -R 8 , R 10 , R 2 ′-R 6 ′, W, and A have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as antibacterial agents.

  本发明提供一个式子(I)的化合物：或其盐或前药，其中R1、R4-R8、R10、R2′-R6′、W和A的任意值均如规范中描述的那样，以及包含式(I)的化合物的组合物。这些化合物可用作抗菌剂。